11 min read
Monthly FDA Guidance and Regulatory News Review - September 2026
This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
Learn More →
Veristat is proud to be participating at a Rare Disease Workshop on July 18, 2018 taking place at Biogen. Veristat's statitiscal and adaptive design expert, Mark Chang, PhD will be will be speaking about the “Controversies in Rare Disease Trial Designs and Personalized Medicine”.
Mark Chang, PhD, Dr. Chang has over 20 years of experience as a statistician designing and implementing both simple and complex adaptive design trials for rare diseases.
11 min read
Oct 21, 2026 Veristat Blog
This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...
8 min read
Sep 21, 2026 Veristat Blog
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...